EA200802247A1 - Схема дозирования кладрибина для лечения рассеянного склероза - Google Patents

Схема дозирования кладрибина для лечения рассеянного склероза

Info

Publication number
EA200802247A1
EA200802247A1 EA200802247A EA200802247A EA200802247A1 EA 200802247 A1 EA200802247 A1 EA 200802247A1 EA 200802247 A EA200802247 A EA 200802247A EA 200802247 A EA200802247 A EA 200802247A EA 200802247 A1 EA200802247 A1 EA 200802247A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
multiple sclerosis
kladribin
dosing scheme
dosing
Prior art date
Application number
EA200802247A
Other languages
English (en)
Other versions
EA020805B1 (ru
Inventor
Джеймс Джр. Брентцель Х.
Мария Лопес-Бреснахан
Назих Аммури
Original Assignee
Лаборатуар Сероно С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Лаборатуар Сероно С.А. filed Critical Лаборатуар Сероно С.А.
Publication of EA200802247A1 publication Critical patent/EA200802247A1/ru
Publication of EA020805B1 publication Critical patent/EA020805B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение относится к применению многократных доз кладрибина в комбинации с бета интерфероном для лечения рассеянного склероза у пациентов, которые резистентны по меньшей мере к одному общепринятому лечению.
EA200802247A 2006-05-24 2007-05-23 Применение комбинации кладрибина и бета-интерферона для лечения рассеянного склероза EA020805B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06114537 2006-05-24
US84547006P 2006-09-18 2006-09-18
PCT/EP2007/055013 WO2007135172A2 (en) 2006-05-24 2007-05-23 Cladribine regimen for treating multiple sclerosis

Publications (2)

Publication Number Publication Date
EA200802247A1 true EA200802247A1 (ru) 2009-06-30
EA020805B1 EA020805B1 (ru) 2015-01-30

Family

ID=38626625

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200802247A EA020805B1 (ru) 2006-05-24 2007-05-23 Применение комбинации кладрибина и бета-интерферона для лечения рассеянного склероза

Country Status (15)

Country Link
US (3) US9925151B2 (ru)
EP (1) EP2026832B1 (ru)
JP (6) JP2009537605A (ru)
KR (1) KR20090019810A (ru)
AR (1) AR061122A1 (ru)
AU (1) AU2007253254B2 (ru)
CA (1) CA2649810A1 (ru)
EA (1) EA020805B1 (ru)
HK (1) HK1127753A1 (ru)
HR (1) HRP20120382T1 (ru)
IL (1) IL195352A0 (ru)
MX (1) MX2008014971A (ru)
PL (1) PL2026832T3 (ru)
WO (1) WO2007135172A2 (ru)
ZA (1) ZA200808852B (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1827461B1 (en) * 2004-12-22 2012-02-29 Merck Serono SA Cladribine regimen for treating multiple sclerosis
AU2007253254B2 (en) 2006-05-24 2013-01-17 Merck Serono Sa Cladribine regimen for treating multiple sclerosis
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2821992A1 (en) 2010-10-01 2012-04-05 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3492109B1 (en) 2011-10-03 2020-03-04 ModernaTX, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
JP2015501844A (ja) 2011-12-16 2015-01-19 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 修飾ヌクレオシド、ヌクレオチドおよび核酸組成物
WO2013120851A1 (en) * 2012-02-13 2013-08-22 Mach-3D Sàrl Method for sharing emotions through the creation of three-dimensional avatars and their interaction through a cloud-based platform
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
EP2833923A4 (en) 2012-04-02 2016-02-24 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
LT2922554T (lt) 2012-11-26 2022-06-27 Modernatx, Inc. Terminaliai modifikuota rnr
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
GB2564717A (en) * 2017-07-21 2019-01-23 Chord Therapeutics S A R L Use of cladribine for treating autoimmune neuromuscular disease
US10849919B2 (en) * 2017-11-24 2020-12-01 Merck Patent Gmbh Cladribine regimen for treating progressive forms of multiple sclerosis
EP3863628B1 (en) * 2018-10-09 2023-12-27 MediciNova, Inc. Combination of ibudilast and interferon-beta and methods of using same

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3273787D1 (en) 1981-02-04 1986-11-20 Japan Found Cancer Human interferon-beta gene
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
CA1269659A (en) 1984-08-06 1990-05-29 Brigham Young University Method for the production of 2'-deoxyadenosine compounds
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US5017691A (en) 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
JPS62153300A (ja) 1985-12-26 1987-07-08 Teijin Ltd ヒト免疫グロブリンＧＦｃ領域蛋白質およびその製造方法
US5310732A (en) 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US5106837A (en) 1988-03-16 1992-04-21 The Scripps Research Institute Adenosine derivatives with therapeutic activity
US4879111A (en) 1986-04-17 1989-11-07 Cetus Corporation Treatment of infections with lymphokines
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
ES2092468T3 (es) 1988-01-22 1996-12-01 Zymogenetics Inc Metodos para producir analogos de receptores secretados.
US4964848A (en) * 1988-06-27 1990-10-23 Bloom Philip M Treatment of multiple sclerosis with lymphocytapheresis and chemo-immunosuppression
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
ES2145744T5 (es) 1991-01-18 2008-02-01 Amgen Inc. Procedimientos para tratar las enfermedades inducidas por el factor de necrosis tumoral.
US5208327A (en) 1991-12-18 1993-05-04 Ortho Pharmaceutical Corporation Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US5641757A (en) 1994-12-21 1997-06-24 Ortho Pharmaceutical Corporation Stable 2-chloro-2'-deoxyadenosine formulations
CA2208484C (en) 1994-12-22 2008-09-23 Ortho Pharmaceutical Corporation Soluble 2-chloro-2'-deoxyadenosine formulations
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
US6013253A (en) 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
EA003789B1 (ru) 1998-04-28 2003-10-30 Апплайд Резеч Системз Арс Холдинг Н.В. КОНЪЮГАТЫ ПОЛИОЛ-β-ИНТЕРФЕРОН
BR9915548A (pt) 1998-10-16 2001-08-14 Biogen Inc Proteìnas de fusão de interferon-beta e usos
US6194395B1 (en) 1999-02-25 2001-02-27 Orthro-Mcneil Pharmaceutical, Inc. Cyclodextrin cladribine formulations
FR2792480B1 (fr) 1999-04-19 2001-06-15 France Telecom Systeme de mise en oeuvre de services telephoniques
WO2000064918A1 (en) 1999-04-28 2000-11-02 Sterrenbeld Biotechnologie North America, Inc. METHOD FOR THE PRODUCTION OF 2-CHLORO-2'-DEOXYADENOSINE (CLADRIBINE) AND ITS 3,5-DI-O-p-TOLUOYL DERIVATIVE
AU782496B2 (en) 1999-07-13 2005-08-04 Bolder Biotechnology, Inc. Immunoglobulin fusion proteins
WO2004028462A2 (en) 2002-09-25 2004-04-08 Brigham Young University, Technology Transfer Office Method for the preparation of 2-halo-2'-deoxyadenosine compounds from 2'-deoxyguanosine
GB2394658A (en) 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
MXPA05008998A (es) 2003-02-25 2005-10-18 Applied Research Systems Uso combinado de ribavirina e interferon beta en enfermedades desmielinizantes.
PT1608344E (pt) * 2003-03-28 2010-09-02 Ares Trading Sa Formulações orais de cladribina
MXPA05010330A (es) 2003-03-28 2006-05-31 Ivax Corp Formulaciones de cladribina para el mejor suministro oral y a traves de la mucosa.
TWI272948B (en) 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
EP1827461B1 (en) * 2004-12-22 2012-02-29 Merck Serono SA Cladribine regimen for treating multiple sclerosis
AU2007253254B2 (en) 2006-05-24 2013-01-17 Merck Serono Sa Cladribine regimen for treating multiple sclerosis

Also Published As

Publication number Publication date
CA2649810A1 (en) 2007-11-29
JP2022162108A (ja) 2022-10-21
IL195352A0 (en) 2011-08-01
JP2009537605A (ja) 2009-10-29
JP6542680B2 (ja) 2019-07-10
WO2007135172A3 (en) 2008-01-24
EP2026832B1 (en) 2012-05-02
HK1127753A1 (en) 2009-10-09
US10555913B2 (en) 2020-02-11
ZA200808852B (en) 2009-12-30
EP2026832A2 (en) 2009-02-25
AU2007253254B2 (en) 2013-01-17
WO2007135172A2 (en) 2007-11-29
JP2018080184A (ja) 2018-05-24
AR061122A1 (es) 2008-08-06
JP7132194B2 (ja) 2022-09-06
US20100021429A1 (en) 2010-01-28
US9925151B2 (en) 2018-03-27
JP2016128443A (ja) 2016-07-14
EA020805B1 (ru) 2015-01-30
AU2007253254A1 (en) 2007-11-29
HRP20120382T1 (hr) 2012-06-30
PL2026832T3 (pl) 2012-08-31
MX2008014971A (es) 2008-12-05
KR20090019810A (ko) 2009-02-25
US20200155477A1 (en) 2020-05-21
US20180207109A1 (en) 2018-07-26
JP2020050651A (ja) 2020-04-02
JP2014208662A (ja) 2014-11-06

Similar Documents

Publication Publication Date Title
EA200802247A1 (ru) Схема дозирования кладрибина для лечения рассеянного склероза
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
CY1121203T1 (el) Θεραπευτικες χρησεις της εμπαγλιφλοζινης
CY1118311T1 (el) Παραγωγα νιτροκατεχολης ως αναστολεις comt που χορηγουνται με ειδικη αγωγη δοσολογιας
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
TN2014000134A1 (en) Therapeutic peptides
UA115122C2 (uk) Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини і cd3, що не є людським
MX347324B (es) Uso de dosis bajas de il-2 para tratar trastornos inflamatorios o relacionados con la autoinmunidad.
MY156951A (en) Micromirs
BR112012016853A2 (pt) "composições farmacêuticas para administração oral de peptídeos de insulina".
UA113849C2 (xx) Застосування сигма-лігандів при болю, пов'язаному з діабетом 2 типу
CY1112320T1 (el) Τιτλοδοτηση της ταπενταδολης
BR112013029256A8 (pt) combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2
CL2009000402A1 (es) Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras.
EA201171043A1 (ru) Композиции и способы длительной терапии с применением аминопиридинов
MX2010006204A (es) Derivados de oxindol 5,6-disubstituidos y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
MA32841B1 (fr) Composés de cycloundeca depsipeptides et leur utilisation comme médicament
MY150931A (en) Substituted oxazolidinones and their use
CR20110552A (es) Tratamiento de transtornos resistentes a la insulina
MY168778A (en) Oligonucleotide chelate complex-polypeptide compositions and methods
EA200702336A1 (ru) ПРИМЕНЕНИЕ 24-норУДХК
UA94781C2 (ru) Применение йота-каррагенана для профилактики или терапевтического лечения риновирусной инфекции
ECSP088997A (es) Régimen de cladribina para el tratamiento de esclerosis múltiple
CY1111840T1 (el) Χρηση του 4-κυκλοπροπυλμεθοξυ-ν-(3,5-διχλωρο-1-οξειδο-πυριδιν-4-υλ)-5-(μεθοξυ)πυριδιν-2-καρβοξαμιδιου για τη θεραπεια κινητικων διαταραχων που σχετιζονται με τη νοσο toy parkinson
CY1118581T1 (el) Νεα χρηση για αλφα-συμπαθομιμητικα με δομη 2-ιμιδαζολινης

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ MD TM